Compare Eli Lilly And Co (LLY) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs New York Times Co — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: Eli Lilly And Co is far larger — about 96.8× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and New York Times Co for 81 Days on average.
| LLY | NYT | |
|---|---|---|
Market Cap | $1.04T | $10.74B |
Volume | 3,064,878 | 2,096,352 |
Sector | Health | Media |
52-Week High | $1.28K | $85.86 |
52-Week Low | $799.57 | $54.66 |
Typical Hold Time | 93 Days | 81 Days |
Enterprise Value | $1.09T | $10.14B |
Dividend Yield | 0.59% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
The New York Times Company (NYT) trades at $66.32, up 2.19% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. The stock shows a bullish technical signal with key support at $65-66 and resistance at $67-68, while maintaining robust profitability with 51.41% gross margins and 13.19% net income margin. Recent developments include a declared $0.23 dividend and ongoing AI copyright litigation.
Outlook remains positive with analyst consensus target of $84 representing 27% upside potential, though risks include the shareholder lawsuit alleging bias and competitive pressures in digital media. The company's strong cash flow generation and dividend payments provide shareholder value, while earnings growth trajectory supports continued valuation expansion if execution remains solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
